How to optimize the treatment of early stage Parkinson's disease

Translational Neurodegeneration

Volumn 4, Issue 1, 2015, Pages

  Stocchi, Fabrizio ^a   Vacca, Laura ^a   Radicati, Fabiana G ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DENERVATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSKINESIA; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; SYMPTOMATOLOGY; TIME TO TREATMENT; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; VALVULAR HEART DISEASE;

EID: 84929305510     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-4-4     Document Type: Review

References (76)

1. Hirsch EC, Jenner P, Przedborski S: Pathogenesis of Parkinson's disease. Mov Disord 2013,28(1):24-30. 10.1002/mds.25032.
2. Rascol O, Fitzer-Attas CJ, Hauser R: A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011,10(5):415-23. 10.1016/S1474-4422(11)70073-4.
3. Schapira AH, Obeso J: Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006,59(3):559-62. 10.1002/ana.20789.
4. Stocchi F, Olanow CW: Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord 2013,28(1):3-7. 10.1002/mds.25337.
5. Shapira AH, Olanow CW: Neuroprotection in Parkinson Disease: mysteries, myths and misconceptions. JAMA 2004, 291:358-64. 10.1001/jama.291.3.358.
6. Gasser T, Hardy J, Mizuno Y: Milestones in PD Genetics. Mov Disord 2011, 26:1042-8. 10.1002/mds.23637.
7. Singleton AB, Farrer MJ, Bonifati V: The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 2013,28(1):14-23. 10.1002/mds.25249.
8. Martin I, Dawson VL, Dawson TM: Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet 2011, 12:301-25. 10.1146/annurev-genom-082410-101440.
9. Olanow CW, Prusiner SB: Is Parkinson's disease a prion disorder. Proc Natl Acad Sci 2009, 106:12571-2. 10.1073/pnas.0906759106.
10. Bezard E, Yue Z, Kirik D, Spillantini MG: Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies. Mov Disord 2013,28(1):61-70. 10.1002/mds.25108.
11. Olanow CW, Kordower J: Modeling Parkinson's disease. Ann Neurol 2009, 66:432-6. 10.1002/ana.21832.
12. Dawson TM, Ko HS, Dawson VL: Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-61. 10.1016/j.neuron.2010.04.034.
13. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al.: For the Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008, 23:2129-70. 10.1002/mds.22340.
14. The Parkinson Progression Marker Initiative (PPMI): Parkinson Progression Marker Initiative. Prog Neurobiol 2011, 95:629-35. 10.1016/j.pneurobio.2011.09.005.
15. Leber P: Slowing the progression of Alzheimer disease: methodological issues. Alzheimer Dis Assoc Disord 1997,11(5):S10-21.
16. Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JVS: Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 2009,11(3):456-64. 10.1208/s12248-009-9123-2.
17. Olanow CW, Hauser R, Jankovic J, Langston W, Lang A, Poewe W, et al.: A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline as a Disease Modifying Therapy in Parkinson's Disease (The ADAGIO Study): Rationale, design, and baseline characteristics. Mov Disord 2008, 23:2194-201. 10.1002/mds.22218.
18. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al.: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-78. 10.1056/NEJMoa0809335.
19. Elm J, The NINDS NET-PD Investigators: Design innovations and baseline findings in a long-term Parkinson's trial: NET-PD LS-1. Mov Disord 2012,27(12):1513-21. 10.1002/mds.25175.
20. Olanow CW, Kieburtz K: Defining disease-modifying therapies for PD-a road map for moving forward. Mov Disord 2010, 25:1774-9. 10.1002/mds.23288.
21. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-58. 10.1002/mds.1090.
22. Olanow CW, Obeso JA, Stocchi F: Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5:677-87. 10.1016/S1474-4422(06)70521-X.
23. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM: Rationale for continuous dopaminergic therapy of Parkinson's disease. Neurology 1989, 39:7-10.
24. Olanow CW, Schapira AHV, Rascol O: Continuous dopaminergic stimulation in the early treatment of PD. Trends Neurosci 2000, 23:117-26.
25. Stocchi F, Vacca L, Ruggieri S, Olanow CW: Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005, 62:905-10.
26. Sage JI, Trooskin S, Sonsalla PK, Heikkila RE, Duvoisin RC: Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988, 24:87-9. 10.1002/ana.410240116.
27. Nilsson D, Hansson L, Johansson K, Nystrom C, Paalzow L, Aquilonius SM: Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998, 97:175-83. 10.1111/j.1600-0447.1998.tb09984.x.
28. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, et al.: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994, 44:913-9. 10.1212/WNL.44.5.913.
29. Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, et al.: Multiple small doses of levodopa plus entacapone produces continuous dopaminergic stimulation and reduces dyskinesia induction in MPTP-treated drug naïve primates. Mov Disord 2005, 20:306-14. 10.1002/mds.20317.
30. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010, 68:18-27. 10.1002/ana.22060.
31. Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira A, Nissinen H, Leinonen M, Stocchi F, for the STRIDE-PD investigators: Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's Disease. Mov Disord 2013,28(8):1064-71. 10.1002/mds.25364.
32. Pearce RK, Banerji T, Jenner P, Marsden CD: De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998, 13:234-41. 10.1002/mds.870130207.
33. Lees AJ, Haddad S, Shaw KM, Kohout LJ, Stern GM: Bromocriptine in parkinsonism. A long-term study. Arch Neurol 1978, 35:503-5. 10.1001/archneur.1978.00500320023005.
34. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M: Longterm treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979, 42:143-50. 10.1136/jnnp.42.2.143.
35. Montastruc JL, Rascol O, Rascol A: A randomised controller study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989, 52:773-5. 10.1136/jnnp.52.6.773.
36. Rinne UK: Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987, 37:826-8. 10.1212/WNL.37.5.826.
37. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-91. 10.1056/NEJM200005183422004.
38. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000, 284:1931-8. 10.1001/jama.284.15.1931.
39. Oertel WH, Wolters E, Sampaio C, Giminez-Roldan S, Bergamasco B, Dujardin M, Dupont E, Gershanik O, Marti Masso JF, Weytjens C, Muyldermans L, Van Zandijcke M, et al.: Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006, 21:343-53. 10.1002/mds.20724.
40. Rinne UK, Bracco F, Chouza C, et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998,55(Suppl 1):23-30.
41. Van Camp G, Flamez A, Cosyns B, et al.: Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004, 363:1179-83. 10.1016/S0140-6736(04)15945-X.
42. Rascol O, Pathak A, Bagheri H, Montastruc JL: Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord 2004, 19:1524-5. 10.1002/mds.20328.
43. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, et al.: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004, 19:656-62. 10.1002/mds.20201.
44. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al.: Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007, 68:1108-15. 10.1212/01.wnl.0000258660.74391.c1.
45. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L: Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008, 24:2883-95. 10.1185/03007990802387130.
46. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, et al.: Randomized, doubleblind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010, 25:2542-9. 10.1002/mds.23317.
47. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH: Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-404. 10.1002/mds.21741.
48. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al.: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-20. 10.1016/S1474-4422(07)70108-4.
49. Frucht S, Fahn S, Shannon KM, Waters CH: A 32-year-old man with progressive spasticity and parkinsonism. Mov Disord 1999, 14:350-7. Publisher Full Text 10.1002/1531-8257(199903)14:2<350::AID-MDS1024>3.0.CO;2-0.
50. Hogl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Nierdermuller U, et al.: Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 2003, 18:319-23. 10.1002/mds.10365.
51. Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, et al.: Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006, 13:209-14. 10.1111/j.1468-1331.2006.01262.x.
52. Brodsky MA, Godbold J, Roth T, Olanow CW: Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003, 18:668-72. 10.1002/mds.10429.
53. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH: A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009, 8:929-37. 10.1016/S1474-4422(09)70225-X.
54. Molina JA, Sainz-Artiga MJ, Fraile A, Jiménez-Jiménez FJ, Villanueva C, Orti-Pareja M, et al.: Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000, 15:869-72. Publisher Full Text 10.1002/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I.
55. Evans AH, Strafella AP, Weintraub D, Stacy M: Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009, 24:1561-70. 10.1002/mds.22505.
56. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al.: Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-95.
57. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, et al.: Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006, 21:1844-50. 10.1002/mds.20988.
58. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K: Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007, 22:1317-9. 10.1002/mds.21292.
59. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, et al.: Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 2010, 25:858-66. 10.1002/mds.22890.
60. Parkinson Study Group CALM Cohort Investigators: Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009, 66:563-70.
61. Hely MA, Morris JG, Reid WG, Trafficante R: Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190-9. 10.1002/mds.20324.
62. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, et al.: Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004, 19:997-1005. 10.1002/mds.20243.
63. Kurlan R: "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology 2005, 64:923-4.
64. Langston JW, Irwin I: MPTP: current concepts and controversies. Clin Neuropharmacol 1986, 9:485-507. 10.1097/00002826-198612000-00001.
65. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328:176-83.
66. Olanow CW, Calne D: Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1992,42(Suppl 4):13-26. discussion 41-18
67. Heinonen EH, Myllylä V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf 1998,19(1):11-22. 10.2165/00002018-199819010-00002.
68. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002, 59:1937-43.
69. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, et al.: Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004, 19:916-23. 10.1002/mds.20145.
70. Olanow W: Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 2009,72(7 Suppl):S59-64.
71. Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB: Pharmacology and neuroprotective properties of rasagiline. J Neural Transm 1996, 48:95-101.
72. Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB: Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 2005, 1053:348-55. 10.1196/annals.1344.030.
73. Gray R, Ives N, Rick C, PD Med Collaborative Group: Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014,384(9949):1196-205. 10.1016/S0140-6736(14)60683-8.
74. Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S, ANDANTE study investigators: Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Mov Disord 2014,29(8):1028-34. 10.1002/mds.25877.
75. Stocchi F, Abbruzzese G, Ceravolo R, Cortelli P, D'Amelio M, De P, et al.: Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology 2014,83(3):215-20. vol. 15 10.1212/WNL.0000000000000587.
76. Stocchi F, The ADAGIO investigators: Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. Eur J Neurol 2014,21(2):257-360.